<table>
<thead>
<tr>
<th>Indication</th>
<th>Heart failure</th>
<th>ICD11 code: BD0Z</th>
</tr>
</thead>
<tbody>
<tr>
<td>INN</td>
<td>Hydrochlorothiazide</td>
<td></td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
<td></td>
</tr>
<tr>
<td>List type</td>
<td>Core</td>
<td></td>
</tr>
</tbody>
</table>
| Formulations | Oral > Liquid: 50 mg per 5 mL  
Oral > Solid: 25 mg |
| EML status history | First added in 1997 (TRS 882)  
Changed in 2003 (TRS 920)  
Changed in 2009 (TRS 958)  
Changed in 2021 (TRS 1035) |
| Sex        | All |
| Age        | Adolescents and adults |
| Therapeutic alternatives | chlorothiazide (ATC codes: C03AA04)  
chlortalidone (ATC codes: C03BA04)  
indapamide (ATC codes: C03BA11) |
| Patent information | Patents have expired in most jurisdictions  
Read more about patents. |

**Wikipedia**  
[Hydrochlorothiazide](https://en.wikipedia.org/wiki/Hydrochlorothiazide)

**DrugBank**  
[Hydrochlorothiazide](https://www.drugbank.ca/drugs/DB00096)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended chlorothiazide, chlortalidone and indapamide be specified as therapeutic alternatives under the square box listing for hydrochlorothiazide on the EML for this indication.